Physician profile

Jonathan Hertz

Pulmonary Disease · Allentown, PA

NPI 1033182324

$490.25

in general payments reported to CMS, 2019-2025

17 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $77.78 2019-2020
Glaxosmithkline, LLC. $65.68 2019-2020
Genentech USA, INC. $46.36 2019
Boehringer Ingelheim Pharmaceuticals, INC. $37.02 2019
Genzyme Corporation $34.77 2019-2020
Jazz Pharmaceuticals INC. $31.29 2019
Sunovion Pharmaceuticals INC. $28.43 2019
Philips North America LLC $26.86 2019
Astrazeneca Pharmaceuticals LP $24.89 2019-2020
Grifols USA, LLC $17.35 2020
Resmed Corp $16.71 2019
Takeda Pharmaceuticals U.S.A., INC. $15.49 2020
Actelion Pharmaceuticals US, INC. $15.47 2019
Shire North American Group INC $14.34 2019
Advanced Respiratory, INC $13.61 2019
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $13.37 2019
E.R. Squibb & Sons, L.L.C. $10.83 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan Hertz

$490.25

in general payments reported 2019-2025

Years
2019-2020
Top company
Mylan Specialty L.P.

https://glasscript.com/doctor/319551/jonathan-hertz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.